Catheter Precision Inc. (NYSE American: VTAK) Stock Volume Soars with Middle East Expansion of VIVO 3D Heart Imaging System

The United States-based medical device company Catheter Precision Inc. (NYSE American: VTAK) gained significant attention on June 20 after announcing its first purchase order from Qatar. In the news release, Catheter Precision revealed that an initial evaluation of its VIVO product was conducted earlier in 2024 at the Hamad Medical Corporation Heart Hospital in Doha.

Image: https://www.abnewswire.com/uploads/53629e2ef4e14a0e9756b6cd49618d9c.jpg

Catheter Precision Inc. (NYSE American: VTAK) surged 5.28% on June 25, 2024, with trading volume hitting 3.09 times the norm hitting an intraday high of $0.7199. The stock climbed an additional 4% in after-hours trading and boasts a 28.9% increase since June 20, 2024. VTAK's trading volumes have seen a notable uptick since June 11, 2024, positioning it in breakout territory, surpassing its 20, 50, and 200-day moving averages. With numerous bullish indicators consistently present, VTAK is an attractive buy during sideways market movements or on dips, as its strong trend is expected to continue this upward trajectory for a while.

Catheter Precision's VIVO (View Into Ventricular Onset) is a revolutionary non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before heart procedures. VIVO streamlines ventricular ablation, saving time and reducing complications. The company, following its expansion strategy, had previously announced this innovation. The company is renowned for its two key innovative products: [https://pr.report/KR3kWIFh], aiding in ventricular arrhythmia source detection pre-procedure, and LockeT [https://pr.report/EJ7gyVt2], a closure retention device. [https://thestreetreports.com/cutting-edge-medical-innovations-propel-catheter-precision-inc-nyse-american-vtak-forward/]

These innovative medical devices, develops cutting-edge products aimed at enhancing patient care for physicians and hospitals. By collaborating with medical professionals, Catheter Precision improves its groundbreaking technologies and existing products, making workflows more efficient and reducing heart procedure times and potential complications. Their product, which received marketing clearance from the U.S. FDA and CE mark approval for the European Union, exemplifies their commitment to elevating healthcare standards.

Featured by Barchart alongside GameStop Corp (NYSE: GME), AMC Entertainment (NYSE: AMC), Novavax (NASDAQ: NVAX), Peraso (NASDAQ: PRSO), Intelligent Bio Solutions Inc (NASDAQ: INBS), Dyadic International Inc. (NASDAQ: DYAI) see: https://www.barchart.com/story/news/26816026/gamestop-raises-214-billion-meme-stocks-buzz-fuels-gains-watch-gme-prso-dyai-vtak-amc

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=catheter-precision-inc-nyse-american-vtak-stock-volume-soars-with-middle-east-expansion-of-vivo-3d-heart-imaging-system]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.